Merck's WINREVAIR Now Listed in Five Canadian Public Programs

Merck announced that British Columbia, Nova Scotia, Quebec, and Veterans Affairs Canada have added WINREVAIR (sotatercept) to their public drug formularies, improving access for Canadians living with pulmonary arterial hypertension (PAH). WINREVAIR is indicated in combination with standard PAH therapy for adults with WHO Group 1 PAH and Functional Class II, III, or IV. This marks a significant step toward expanding access to therapies for PAH patients.